Reduction in Test Positivity for Common Cold Coronaviruses After SARS-CoV-2 Spread
Overview
Following widespread SARS-CoV-2 infections and COVID-19 vaccination, test positivity for common cold coronaviruses (ccCoVs) significantly decreased by approximately 60%, while respiratory syncytial virus (RSV) and influenza virus (IV) positivity remained unchanged. This suggests a unique interaction between SARS-CoV-2 immunity and ccCoVs.
Background
Before the COVID-19 pandemic, respiratory viruses such as ccCoVs, RSV, and IV were common causes of respiratory infections with overlapping clinical presentations. Unlike RSV and IV, ccCoVs share genetic and structural similarities with SARS-CoV-2, potentially enabling cross-reactive immune responses. Prior ccCoV infections have been linked to preexisting immunity against SARS-CoV-2 and reduced COVID-19 severity. The study investigates changes in ccCoV, RSV, and IV incidence before and after the SARS-CoV-2 Omicron surge and widespread vaccination.
Data Highlights
Virus
Period 1 (Pre-COVID-19)
Period 2 (Post-Omicron & Vaccination)
Change in Test Positivity
Common Cold Coronaviruses (ccCoVs)
Baseline positivity
Significantly lower positivity
~60% lower odds of detection
Respiratory Syncytial Virus (RSV)
Baseline positivity
No significant change
No change in odds
Influenza Virus (IV)
Baseline positivity
No significant change
No change in odds
Key Findings
Test positivity for ccCoVs decreased significantly after widespread SARS-CoV-2 infection and vaccination.
There was approximately a 60% reduction in the odds of ccCoV detection in the post-Omicron period.
RSV and IV test positivity did not show significant changes between pre- and post-pandemic periods.
Shared genetic and structural features among coronaviruses may contribute to cross-reactive immunity affecting ccCoV incidence.
Behavioral and healthcare practice changes may also influence the observed decrease in ccCoV positivity.
Clinical Implications
Clinicians should be aware that widespread SARS-CoV-2 immunity may reduce the incidence of ccCoV infections, potentially altering the epidemiology of common respiratory viruses. Diagnostic considerations for respiratory infections may need adjustment given the decreased prevalence of ccCoVs post-pandemic. Understanding cross-reactive immunity could inform future vaccine strategies targeting multiple coronaviruses.
Conclusion
The study demonstrates a significant reduction in common cold coronavirus positivity following widespread SARS-CoV-2 infections and vaccination, likely due to cross-reactive immunity and behavioral changes. RSV and influenza virus incidences remained stable, highlighting a unique interaction between SARS-CoV-2 and related coronaviruses.
References
Boston Medical Center Study 2024 -- Reduction in Test Positivity for Common Cold Coronaviruses Following Widespread SARS-CoV-2 Infections
